Project Grant HT94252410219

GRANT AWARD SUMMARY Mayo Clinic received a $412,429 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to conduct research on novel therapeutic combinations for high-grade serous ovarian cancer (HGSOC). The award period extends from August 1, 2025, through July 31, 2027. The research focuses on developing and mechanistically evaluating drug-induced replication stress markers as therapeutic targets, specifically investigating the...

This $424,836 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to identify and target drug-tolerant persister cells in small cell lung cancer (SCLC). The University of Texas MD Anderson Cancer Center, the awardee, will use this funding to procure and analyze SCLC patient samples and models across different clinical timepoints. The goal is to better understand the mechanisms underlying SCLC's high initial response rates to...

This $680,507 Project Grant was awarded on April 1, 2025 by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of California, San Francisco. The grant aims to elucidate mechanisms of cancer persister cell rewiring and identify druggable targets to eradicate persistence in KRAS-mutant non-small cell lung cancer. The key objectives are to: 1) illuminate signals that promote persistence in physiological contexts, 2) identify and validate targets that inhibit...

The National Cancer Institute (NCI) awarded a $151,000 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to The Medical University of South Carolina (MUSC) to investigate the role of polyploid cancer cells in high-grade serous ovarian carcinoma (HGSOC). The project aims to: 1) Define essential genes for the polyploid cancer cell lifecycle and its critical transition stages using CRISPR-Cas9 screening, and 2) Determine the expression of putative polyploid cancer...

The University of Houston System was awarded a $398,282 federal Project Grant by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396). The 5-year grant, running from April 2025 to March 2030, will fund research to evaluate the role of metabolism in persister cell survival in mammalian cell populations. Persister cells are a small fraction of quiescent cells in a tumor that exhibit temporary tolerance to drugs, which can lead to tumor relapse and the emergence...

Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $164,000 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective September 1, 2025 through August 31, 2027. The grant funds research into dissecting clonal determinants of platinum and poly(adenosine diphosphate)-ribose polymerase inhibitor (PARPI) cross-resistance in high-grade serous ovarian cancer (HGSOC). The research...

The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $985,876 project grant to The Trustees of Columbia University in the City of New York to conduct research on "TARGETING PARP1 TRAPPING TO OVERCOME PARP INHIBITOR RESISTANCE FOR BRCAMUT OVARIAN CANCERS." The grant, which runs from April 15, 2024 to April 18, 2024, aims to develop new treatments for ovarian cancer in patients with BRCA mutations by investigating strategies to...

This $816,676 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports a study by the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) to conduct a multiomic evaluation of ovarian cancer responses to heated intraperitoneal chemotherapy (HIPEC). The 3-year study, with a period of performance from September 30, 2024 to August 31, 2027, aims to advance understanding of how HIPEC...

The federal Project Grant award titled "EXPLOITING ABSENCE OF TP53 MUTATIONS IN EPITHELIAL OVARIAN CANCER WITH NEXT-GENERATION P53-STABILIZING AGENTS" was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The $1,178,136 award to the University of Pennsylvania will support advanced biomedical research aimed at developing novel diagnostic tools, therapeutic interventions, and clinical practice guidelines to address critical...

This $2,014,500 project grant from the Defense Health Agency was awarded to Health Research, Inc. - Roswell Park Division to conduct a randomized Phase 2 clinical trial evaluating pembrolizumab combined with bevacizumab, with or without the anti-CD40 agonist CDX-1140, in patients with recurrent ovarian cancer. The grant was provided under the Department of Defense's Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform healthcare for...